BeiGene (BGNE) News Today → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free BGNE Stock Alerts $172.85 +1.82 (+1.06%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 6:21 AM | marketbeat.comBNP Paribas Financial Markets Boosts Stake in BeiGene, Ltd. (NASDAQ:BGNE)BNP Paribas Financial Markets raised its position in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 7,724.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,307 shares of the company's stock afMay 15 at 5:57 PM | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Sanara MedTech (SMTI)May 14, 2024 | marketbeat.comBarings LLC Makes New $10.89 Million Investment in BeiGene, Ltd. (NASDAQ:BGNE)Barings LLC acquired a new stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 60,379 shares of the company's stock, valued at approximately $10,890,000. Barings LLC oMay 14, 2024 | businesswire.comBeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024May 14, 2024 | americanbankingnews.comBeiGene, Ltd. (NASDAQ:BGNE) Given Average Rating of "Moderate Buy" by BrokeragesMay 13, 2024 | americanbankingnews.comBeiGene, Ltd. (NASDAQ:BGNE) to Post Q2 2024 Earnings of ($2.36) Per Share, Leerink Partnrs ForecastsMay 12, 2024 | americanbankingnews.comBeiGene (NASDAQ:BGNE) Price Target Raised to $254.00May 12, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for BeiGene, Ltd.'s FY2027 Earnings (NASDAQ:BGNE)May 11, 2024 | finance.yahoo.comThe BeiGene, Ltd. (NASDAQ:BGNE) First-Quarter Results Are Out And Analysts Have Published New ForecastsMay 10, 2024 | marketbeat.comLeerink Partnrs Weighs in on BeiGene, Ltd.'s FY2027 Earnings (NASDAQ:BGNE)BeiGene, Ltd. (NASDAQ:BGNE - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2027 EPS estimates for BeiGene in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn $7.76 per share for the year, up froMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for BeiGene on Strong Q4 Performance and Promising Brukinsa SalesMay 9, 2024 | marketbeat.comBeiGene (NASDAQ:BGNE) Issues Earnings Results, Beats Estimates By $0.66 EPSBeiGene (NASDAQ:BGNE - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($2.41) EPS for the quarter, beating the consensus estimate of ($3.07) by $0.66. The firm had revenue of $751.70 million during the quarter, compared to analyst estimates of $670.09 million. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The business's revenue for the quarter was up 67.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($3.34) EPS.May 9, 2024 | finance.yahoo.comBeiGene First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | investorplace.comBGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | de.investing.comBeiGene ADS: EPS übertrifft Schätzungen um 0,51 $ - Umsatz besser als erwartetMay 8, 2024 | finance.yahoo.comBeiGene Reports First Quarter 2024 Financial Results and Business UpdatesMay 2, 2024 | marketbeat.comVan ECK Associates Corp Has $14.92 Million Stake in BeiGene, Ltd. (NASDAQ:BGNE)Van ECK Associates Corp cut its position in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 15.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 82,696 shares of the company's stock after selling 15,454 shares duriApril 29, 2024 | marketbeat.comBeiGene, Ltd. (NASDAQ:BGNE) Shares Purchased by abrdn plcabrdn plc boosted its holdings in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 1,346.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,138 shares of the company's stock after acquiring an additional 19,677 shaApril 26, 2024 | benzinga.comHillhouse Boosts Longi Position After Robe, As It Pivots To Global FocusApril 26, 2024 | finanznachrichten.deBeiGene, Ltd.: BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability ReportApril 26, 2024 | businesswire.comBeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability ReportApril 26, 2024 | marketbeat.comHandelsbanken Fonder AB Sells 6,529 Shares of BeiGene, Ltd. (NASDAQ:BGNE)Handelsbanken Fonder AB trimmed its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 23.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,280 shares of the company's stock afteApril 25, 2024 | marketbeat.comBeiGene (NASDAQ:BGNE) Trading 4.3% Higher After Analyst UpgradeBeiGene (NASDAQ:BGNE) Trading 4.3% Higher on Analyst UpgradeApril 24, 2024 | markets.businessinsider.comEvaluating BeiGene: Insights From 6 Financial AnalystsApril 24, 2024 | businesswire.comGlobal Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual MeetingApril 24, 2024 | marketbeat.comBeiGene (NASDAQ:BGNE) Given New $236.00 Price Target at TD CowenTD Cowen boosted their target price on shares of BeiGene from $235.00 to $236.00 and gave the stock a "buy" rating in a research report on Wednesday.April 23, 2024 | msn.comEU regulators approve BeiGene's tislelizumab for lung cancerApril 23, 2024 | finance.yahoo.comWith 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional ownersApril 23, 2024 | businesswire.comBeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung CancerApril 19, 2024 | marketbeat.comBeiGene (NASDAQ:BGNE) Shares Down 2.4% BeiGene (NASDAQ:BGNE) Shares Down 2.4%April 17, 2024 | marketbeat.comBeiGene (NASDAQ:BGNE) Sets New 12-Month Low at $131.50BeiGene (NASDAQ:BGNE) Reaches New 12-Month Low at $131.50April 14, 2024 | nasdaq.comBeiGene Becomes Oversold (BGNE)April 14, 2024 | marketbeat.comBeiGene, Ltd. (NASDAQ:BGNE) Shares Sold by DekaBank Deutsche GirozentraleDekaBank Deutsche Girozentrale lessened its stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 54.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 13,600 shares of the company's stock after selling 16,000 sharApril 13, 2024 | investing.comBeiGene CEO John Oyler sells shares worth over $7.4 millionApril 12, 2024 | insidertrades.comInsider Selling: BeiGene, Ltd. (NASDAQ:BGNE) CEO Sells 26,716 Shares of StockApril 11, 2024 | marketbeat.comBeiGene, Ltd. (NASDAQ:BGNE) CEO Sells $3,977,745.24 in StockBeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) CEO John Oyler sold 26,716 shares of the stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the completion of the transaction, the chief executive officer now owns 12,084 shares in the company, valued at approximately $1,799,186.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website.April 9, 2024 | marketbeat.comBeiGene (NASDAQ:BGNE) Shares Gap Up to $149.75BeiGene (NASDAQ:BGNE) Shares Gap Up to $149.75April 8, 2024 | marketbeat.comBeiGene (NASDAQ:BGNE) Price Target Cut to $164.30 by Analysts at Bank of AmericaBank of America decreased their price target on shares of BeiGene from $179.30 to $164.30 and set a "neutral" rating on the stock in a report on Monday.March 31, 2024 | marketbeat.comBeiGene, Ltd. (NASDAQ:BGNE) Short Interest UpdateBeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 1,730,000 shares, a decrease of 10.4% from the February 29th total of 1,930,000 shares. Based on an average daily volume of 294,100 shares, the short-interest ratio is currently 5.9 days.March 27, 2024 | markets.businessinsider.com4 Analysts Assess BeiGene: What You Need To KnowMarch 27, 2024 | finance.yahoo.comShareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past weekMarch 27, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)March 27, 2024 | marketbeat.comSanford C. Bernstein Trims BeiGene (NASDAQ:BGNE) Target Price to $161.00Sanford C. Bernstein decreased their price target on shares of BeiGene from $196.00 to $161.00 and set a "market perform" rating on the stock in a research report on Wednesday.March 25, 2024 | marketbeat.comBeiGene, Ltd. (NASDAQ:BGNE) Shares Sold by Matthews International Capital Management LLCMatthews International Capital Management LLC decreased its stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 65.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,902 shares of the company's stock aMarch 25, 2024 | marketbeat.comWellington Management Group LLP Buys 20,239 Shares of BeiGene, Ltd. (NASDAQ:BGNE)Wellington Management Group LLP increased its stake in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 57.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,478 shares of the company's stock after acquiring an aMarch 22, 2024 | investing.comBeiGene appoints new principal accounting officerMarch 20, 2024 | marketbeat.comBeiGene (NASDAQ:BGNE) Price Target Raised to $186.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. boosted their target price on BeiGene from $184.00 to $186.00 and gave the stock an "overweight" rating in a research note on Tuesday.March 19, 2024 | marketbeat.comBeiGene, Ltd. (NASDAQ:BGNE) Short Interest Up 10.3% in FebruaryBeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) saw a large growth in short interest in the month of February. As of February 29th, there was short interest totalling 1,930,000 shares, a growth of 10.3% from the February 14th total of 1,750,000 shares. Based on an average trading volume of 292,000 shares, the days-to-cover ratio is presently 6.6 days.March 16, 2024 | finance.yahoo.comBGNE Apr 2024 140.000 putMarch 16, 2024 | finance.yahoo.comBGNE Apr 2024 220.000 call Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market. Click for his six specific AI stock in the crosshairs BGNE Media Mentions By Week BGNE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BGNE News Sentiment▼0.940.44▲Average Medical News Sentiment BGNE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BGNE Articles This Week▼124▲BGNE Articles Average Week Get BeiGene News Delivered to You Automatically Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TEVA News Today BMRN News Today VTRS News Today SRPT News Today RDY News Today UTHR News Today GMAB News Today ALNY News Today CTLT News Today ROIV News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BGNE) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss RatingsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeiGene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
